By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Pharmaceutical Inc.  

1125 Trenton-Harbourton Road

Titusville  New Jersey  08560  U.S.A.
Phone: 609-730-2000 Fax: n/a



Company News
Janssen Pharmaceutical Release: Real-World Evidence Shows Oral INVOKANA 300 Mg Demonstrates Comparable A1C Reduction And Control To Injectable GLP-1 Receptor Agonists 5/8/2017 6:35:30 AM
Janssen Pharmaceutical Announces HealtheVoices Impact Fund 4/25/2017 9:41:00 AM
Janssen Pharmaceutical Collaborates With Premier, Inc. On Unique Study To Improve Stroke Risk Management Among Hospitalized Patients With Atrial Fibrillation 4/3/2017 9:09:06 AM
Ligand (LGND) Announces Licensing Partner Janssen Pharmaceutical Has Filed An IND For An Antibody Discovered Using The OmniAb Technology 3/28/2017 8:32:26 AM
Janssen Pharmaceutical Release: New Phase III Study Finds XARELTO To Be Superior To Aspirin For Long-Term Prevention Of Recurrent Blood Clots Without Observing Any Significant Increase In Major Bleeding In Patients With Venous Thromboembolism 3/20/2017 6:45:41 AM
Exclusive: Janssen Pharmaceutical Just Came Clean on Drug Pricing Data 2/28/2017 7:11:52 AM
Renova Therapeutics Enters Into Agreement To Receive Stresscopin Investigational New Drug File From Janssen Pharmaceutical 2/6/2017 9:14:18 AM
Bird Rock Bio Release: Biopharma Receives Approval To Start First In Human Clinical Trial For Namacizumab, Enters Into Agreement With GE Healthcare For Process Development And Scale-Up To Provide Clinical Phase 2 Cgmp Material, And Enters Into A Collaboration And Option Agreement With Janssen Pharmaceutical 1/11/2017 6:16:09 AM
Janssen Pharmaceutical Wins Prestigious International Prix Galien Award For MDR-TB Treatment 12/9/2016 9:31:11 AM
Janssen Pharmaceutical Release: New Analysis Shows People With Cancer Who Received XARELTO (Rivaroxaban) For Blood Clots Had Fewer ER Visits And Lower Healthcare Costs Than Those Given Standard Treatment 12/6/2016 8:49:13 AM